CN111643634B - Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia - Google Patents
Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia Download PDFInfo
- Publication number
- CN111643634B CN111643634B CN202010393398.5A CN202010393398A CN111643634B CN 111643634 B CN111643634 B CN 111643634B CN 202010393398 A CN202010393398 A CN 202010393398A CN 111643634 B CN111643634 B CN 111643634B
- Authority
- CN
- China
- Prior art keywords
- parts
- nucleic acid
- chinese medicine
- traditional chinese
- asymptomatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 101
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 62
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 62
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 62
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 56
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 35
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 28
- 235000006533 astragalus Nutrition 0.000 claims abstract description 28
- 241000132012 Atractylodes Species 0.000 claims abstract description 26
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 26
- 244000197580 Poria cocos Species 0.000 claims abstract description 26
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 26
- 240000004510 Agastache rugosa Species 0.000 claims abstract description 23
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 22
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 21
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 18
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 29
- 208000024891 symptom Diseases 0.000 claims description 26
- 230000007812 deficiency Effects 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 244000144725 Amygdalus communis Species 0.000 claims description 8
- 208000031975 Yang Deficiency Diseases 0.000 claims description 7
- 208000031971 Yin Deficiency Diseases 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000024335 physical disease Diseases 0.000 claims description 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 3
- 241000037740 Coptis chinensis Species 0.000 claims description 3
- 244000046095 Psophocarpus tetragonolobus Species 0.000 claims description 3
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 235000017803 cinnamon Nutrition 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000268590 Euryale ferox Species 0.000 claims description 2
- 235000006487 Euryale ferox Nutrition 0.000 claims description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 2
- 244000077995 Coix lacryma jobi Species 0.000 claims 1
- 241000735527 Eupatorium Species 0.000 claims 1
- 240000007171 Imperata cylindrica Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000008859 change Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000004199 lung function Effects 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 60
- 210000000952 spleen Anatomy 0.000 description 46
- 238000002591 computed tomography Methods 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 23
- 230000001717 pathogenic effect Effects 0.000 description 21
- 210000002784 stomach Anatomy 0.000 description 20
- 238000005728 strengthening Methods 0.000 description 20
- 206010062717 Increased upper airway secretion Diseases 0.000 description 18
- 208000026435 phlegm Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 15
- 244000052769 pathogen Species 0.000 description 12
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 9
- 206010011224 Cough Diseases 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 235000021251 pulses Nutrition 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 241001061264 Astragalus Species 0.000 description 6
- 241001522129 Pinellia Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 206010000060 Abdominal distension Diseases 0.000 description 4
- 235000011437 Amygdalus communis Nutrition 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 4
- 235000020224 almond Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000004202 respiratory function Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241001598107 Imperata Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010052251 Respiratory tract congestion Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241001671204 Stemona Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 239000001215 curcuma longa l. root Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000005181 root of the tongue Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000009571 yupingfeng Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine prescription for treating asymptomatic nucleic acid positive coronavirus pneumonia, which is a basic prescription of the traditional Chinese medicine prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-12 parts of codonopsis pilosula, 3-10 parts of fried bighead atractylodes rhizome, 3-10 parts of rhizoma atractylodis, 3-10 parts of poria cocos, 3-10 parts of dried orange peel, 3-10 parts of wrinkled gianthyssop herb, 2-6 parts of fructus amomi, 6-15 parts of pericarpium trichosanthis, 6-15 parts of roasted radix stemonae, 10-20 parts of raw astragalus membranaceus, 3-10 parts of divaricate saposhnikovia root, 2-6 parts of bitter apricot seed, 3-10 parts of rhizoma curcumae longae and 6-15 parts of rhizoma pinelliae preparata. The Chinese medicinal formula has simple and proper compatibility, and the curative effect is fully verified through clinical application. The traditional Chinese medicine prescription can effectively relieve the change of the COVID-19 nucleic acid into negative and the image absorption, can recover the lung function to a certain extent, and improves the immunity of patients.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine prescription for treating asymptomatic nucleic acid positive coronavirus pneumonia.
Background
The novel coronavirus pneumonia (covi-19) refers to a lower respiratory tract inflammatory syndrome with fever and insomnia as main first symptoms caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) infection. The early stage of the disease is often accompanied by insomnia, little phlegm, low fever or no heat, aversion to cold, chest distress and body weight and hypodynamia, the further development of the disease may cause insomnia, thick phlegm, fever or high fever, chest distress and hypodynamia, constipation and abdominal distension, dry cough, choking cough, body heat and asthma in the middle stage of the disease, severe patients can have dyspnea and hypoxemia, and the severe patients can rapidly progress to acute respiratory distress syndrome, sepsis shock, metabolic acidosis which is difficult to correct, blood coagulation dysfunction, multi-organ functional failure and the like to threaten life. China brings COVID-19 into the category of infectious diseases of class B and carries out prevention and control according to the infectious diseases of class A. Because the latent period is long, the early clinical symptoms are atypical, but the transmission speed is high, the infectivity is strong, and the disease has the characteristics of high incidence and rapid disease development. It is important to note that epidemiology has confirmed that every age group is not resistant to the novel coronavirus, and the patients can be infected as long as the transmission conditions are met, but most of the patients become diagnosed latent cases or asymptomatic infectors after infection, the occurrence of COVID-19 asymptomatic infectors may be related to exposure time, personal immune status, basic diseases and the like, and the patients with strong self-resistance to the virus may be asymptomatic infectors. Professional institutions and experts including the national health committee news agency and relevant academicians emphasize that screening, isolation, follow-up visits and diagnosis and treatment of asymptomatic patients must be considered to prevent the patients from infecting the population, developing severe cases and critical cases and the like. Scientific research finds that asymptomatic infected patients also have strong infectivity, and can become main human-borne infection ways and long-term latent risks in the victory stage of epidemic situation control in China.
Nonetheless, at present, there is no ideal therapeutic approach to COVID-19, and vaccine development is remote and promiscuous. The new experiments on old drugs of some original antiviral drugs do not achieve ideal clinical curative effects, and large side effects are shown, such as Reidesvir, gram-force ganoderma, virus targeted therapeutic drugs or multi-drug combination and the like which are proved in clinical tests to be not specific drugs, and the targeted therapeutic drugs aiming at ACE2 receptors are only in the drug research process. The clinical treatment course shows that the hormone shock treatment for the patient with serious symptoms can not improve the prognosis of the patient, and complications such as femoral head necrosis, immunosuppression and the like can occur.
Though ancient Chinese medicine does not have the name of novel coronavirus pneumonia, the pathogenesis characteristics of the pneumonia are recorded in ancient books related to warm diseases in Chinese medicine, the disease belongs to the category of cold-dampness (plague) in Chinese medicine, the disease is transmitted from person to person through droplets and contact, and the disease accords with the indications of 'plain question & academy treatise': the pestilence discussion that the five epidemic diseases are all easy to infect, have no problem about the size and have similar symptoms; the cold-dampness climate background and the cold-dampness symptoms of early infected patients are analyzed, if the patients have symptoms of aversion to cold and fever, dry cough with little phlegm, chest distress and short breath and abdominal distension and diarrhea, which are shown by cold-dampness attacking the exterior, obstructing the lung and obstructing the spleen, the disease belongs to the cold-dampness epidemic in traditional Chinese medicine, while the epidemic toxin can transmit and damage the heart, the liver and the kidney, and the cold-dampness impairing yang is taken as a main line, and has the symptoms of heat transformation, dryness, yin impairment, stasis generation, block and desertion and the like. Traditional Chinese medicine has no record on asymptomatic infected persons, which belong to a special pathogen group of 'with or without symptoms', but intervention and treatment on asymptomatic patients are bound to be in a troublesome condition of 'clear and identifiable' or 'clear and identifiable'.
The classic theory of traditional Chinese medicine considers that the pathogenic mechanism of cold-dampness epidemic pathogenic factor is that the common symptoms of cold-dampness are too much to be disastrous, just as the carrier of the four saint heart sources: "six qi and five elements are all indicated for internal injury, qi deviation in the body, and external affection due to the natural qi deviation. This suggests that we need to focus on the overall understanding and the concept of treatment based on syndrome differentiation and treatment under the guidance of the theory of "external feeling of flatulence" and develop the prevention and treatment technologies of "constitution based on three causes, treatment based on body differentiation" and "prevention and treatment without indication and prior prevention of disease" in traditional Chinese medicine, in addition to the application of isolation, protection and western medicine antiviral treatment. From the disease location, the pathogenic factors invade the lung. The lung is the portal of respiration, and the lung is inevitably injured by the sudden qi coming from the mouth and nose. The records in Ling Shu & Jing Mai (Ling Shu & Jing Mai) are: the pulse of lung-hand taiyin originates from the middle energizer, runs down the large intestine and circulates through the stomach mouth, and the upper diaphragm belongs to the lung. "indicate that the lung diseases are inevitably transmitted to the stomach and intestine, the viscera and meridians are mutually connected, often affecting the spleen, stomach, large intestine, heart, liver, kidney and other viscera, and the disease and treatment should be treated according to the syndrome differentiation of the triple energizer, six meridians, wei-defensive qi, ying-qi and blood, so as to reduce the risk of infection and disease transmission.
In the face of the defects of the treatment of the COVID-19, the traditional Chinese medicine has special advantages, and clinical experience of hospitals shows that the traditional Chinese medicine treatment has exact effect on early-stage and light-symptom asymptomatic patients. In the early stage of the disease, the cold-dampness stagnates in the lung and attacks the exterior, so the treatment should be to eliminate dampness and cold, ventilate lung and expel pathogenic factors, strengthen the exterior and protect the defensive system; in the convalescent stage, qi deficiency of lung and spleen should be treated by clearing away the residual pathogens, ventilating lung and activating spleen, strengthening body resistance and eliminating dampness. The Chinese medicine also shows good effect on the prevention of the disease, and the statement of Su Wen & four-qi regulating the spirit: "not cure the disease before cure, not cure the disease after disorder. "indicate that the individual treatments mainly for eliminating dampness and relieving exterior syndrome due to dampness, deficiency, cold and heat should be formulated to strengthen healthy qi, strengthen physique and avoid poison gas when no disease occurs, so as to prevent the transmission and transformation of diseases. Through dialectical treatment of traditional Chinese medicines on the disease condition, the traditional Chinese medicines are found to be capable of assisting the nucleic acid of patients with the COVID-19 mild disease to turn negative to a certain extent, promoting the absorption of inflammatory exudation of lung of CT images, being beneficial to the respiratory function of the patients, being safe to use for a long time and benefiting more patients. Therefore, the comprehensive development of safe and effective Chinese medicinal preparations with less side effects becomes a hotspot and difficulty in the research and development of the current COVID-19 medicaments.
Disclosure of Invention
In order to effectively assist the covi-19 asymptomatic patient to convert nucleic acid into negative, promote the absorption of inflammatory exudation in the lung of a CT image, facilitate the respiratory function of the patient and reduce the infection rate and the conversion rate of the novel coronavirus pneumonia (covi-19). The invention aims to provide a traditional Chinese medicine prescription for treating asymptomatic nucleic acid positive coronavirus pneumonia; further, a method for treating asymptomatic nucleic acid positive coronavirus pneumonia with yang deficiency and cold constitution diseases is provided; still further, there is provided a method for treating asymptomatic nucleic acid-positive coronavirus pneumonia and febrile disease; still further, there is provided a method for treating asymptomatic nucleic acid-positive coronavirus pneumonia and wet physical condition; further, a method for treating asymptomatic nucleic acid positive coronavirus pneumonia with yin deficiency and deficiency-fire constitutional diseases is provided; further, it provides a method for treating asymptomatic nucleic acid positive coronavirus pneumonia with qi deficiency and blood stasis.
The purpose of the invention is realized by the following modes:
a traditional Chinese medicine prescription for treating asymptomatic nucleic acid positive coronavirus pneumonia is composed of the following raw material medicines in parts by weight: 3-12 parts of codonopsis pilosula, 3-10 parts of fried bighead atractylodes rhizome, 3-10 parts of rhizoma atractylodis, 3-10 parts of poria cocos, 3-10 parts of dried orange peel, 3-10 parts of wrinkled gianthyssop herb, 2-6 parts of fructus amomi, 6-15 parts of pericarpium trichosanthis, 6-15 parts of roasted radix stemonae, 10-20 parts of raw astragalus membranaceus, 3-10 parts of divaricate saposhnikovia root, 2-6 parts of bitter apricot seed, 3-10 parts of rhizoma curcumae longae and 6-15 parts of rhizoma pinelliae preparata. The compatible prescription is a basic prescription of the traditional Chinese medicine prescription for treating asymptomatic patients of the new coronavirus pneumonia.
Further, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight: 5-10 parts of codonopsis pilosula, 3-8 parts of fried bighead atractylodes rhizome, 3-8 parts of rhizoma atractylodis, 3-8 parts of poria cocos, 3-8 parts of dried orange peel, 3-8 parts of wrinkled gianthyssop herb, 2-5 parts of fructus amomi, 6-12 parts of pericarpium trichosanthis, 6-12 parts of roasted radix stemonae, 10-18 parts of raw astragalus membranaceus, 3-8 parts of divaricate saposhnikovia root, 2-5 parts of bitter apricot seed, 3-8 parts of rhizoma curcumae longae and 6-12 parts of rhizoma pinelliae preparata.
Furthermore, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of divaricate saposhnikovia root, 3 parts of bitter almond, 5 parts of rhizoma wenyujin concinnae and 10 parts of rhizoma pinelliae preparata.
Furthermore, the traditional Chinese medicine formula for treating the asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight for the yang deficiency and cold constitution diseases: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of radix sileris, 3 parts of bitter apricot kernel, 5 parts of rhizoma curcumae longae, 10 parts of rhizoma pinelliae preparata, 3 parts of cinnamon and 5 parts of dried ginger.
Furthermore, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight for the heat constitutional disease: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of radix sileris, 3 parts of bitter apricot kernel, 5 parts of rhizoma wenyujin concinna, 10 parts of rhizoma pinelliae preparata, 5 parts of coptis chinensis and 10 parts of lalang grass rhizome.
Furthermore, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight for the damp constitutional disease: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of radix sileris, 3 parts of bitter apricot kernel, 5 parts of rhizoma wenyujin concisum, 10 parts of rhizoma pinelliae preparata, 10 parts of herba eupatorii and 10 parts of semen coicis.
Furthermore, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight for the disease symptoms of yin deficiency and deficient fire constitution: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of radix sileris, 3 parts of bitter apricot kernel, 5 parts of rhizoma wenyujin concinnatae, 10 parts of rhizoma pinelliae preparata, 10 parts of radix ophiopogonis and 10 parts of rhizoma polygonati.
Furthermore, the traditional Chinese medicine formula for treating asymptomatic nucleic acid positive coronavirus pneumonia comprises the following components in parts by weight for the disease symptoms of body qi deficiency and blood stasis: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of radix sileris, 3 parts of bitter apricot kernel, 5 parts of rhizoma wenyujin concisum, 10 parts of rhizoma pinelliae preparata, 10 parts of hyacinth bean, 10 parts of gordon euryale seed and 6 parts of salvia miltiorrhiza.
Furthermore, the Chinese medicinal formula for treating the asymptomatic nucleic acid positive coronavirus pneumonia is prepared into decoction, capsules, pills, granules, tablets or oral liquid.
Further, the Chinese medicinal preparation for treating asymptomatic nucleic acid positive coronavirus pneumonia as described above, wherein the coronavirus is CODVID-19; the name is a name of a novel coronavirus formally released by the world health organization, which is called as Corona Virus Disease 2019.
Furthermore, the Chinese medicinal preparation for treating the asymptomatic nucleic acid positive coronavirus pneumonia is used as an effective ingredient for preparing a medicament related to the treatment of the asymptomatic nucleic acid positive coronavirus pneumonia.
The latent medicine-resolving medical theory of the formula of the traditional Chinese medicine is as follows:
(1) the creation and exploration process of the technical scheme of the invention
Because the novel coronavirus COVID-19 has the characteristics of abrupt change of disease conditions, strong infectivity, high mortality and the like, the research team of the invention mainly treats patients with nucleic acid positive definite diagnosis mild disease by adopting a traditional Chinese medicine treatment means. In the face of sudden new virus attack on human life health, the outstanding advantages of small toxic and side effects of traditional Chinese medicine, excellence in overall treatment and the like are combined, and according to clinical practice, the confirmed asymptomatic patient is found to have greasy tongue coating and exudation in CT, and has the disease mechanism of damp pathogen, and the disease is located in the lung. The research team of the invention rapidly develops expert formula dosage argumentation, aims at the prominent clinical representation of 'positive asymptomatic', and the reason of external infection and toxin, treats dampness by strengthening spleen as the functional aim of reducing phlegm, and the classical formula has the compatibility of various medicines such as 'Sijunzi decoction', 'Buzhong Yiqi decoction', 'Yupingfeng powder' and 'Baidu powder', and the invention creates screening and exploration through the pathogenesis of disease, the compatibility of medicines, the dosage of medicines, the clinical taking of patients with small samples and the like. Finally, the traditional Chinese medicine basic prescription is determined, and the traditional Chinese medicine basic prescription is applied to asymptomatic patients in actual use of resisting the new coronary pneumonia, but the lung is shown in CT examination, and the nucleic acid examination is positive. The formula is as follows: radix Codonopsis, parched Atractylodis rhizoma, rhizoma Atractylodis, Poria, pericarpium Citri Tangerinae, herba Agastaches, fructus Amomi, pericarpium Trichosanthis, radix Stemonae preparata, radix astragali, radix Saposhnikoviae, semen Armeniacae amarum, rhizoma Wenyujin Concisa, and purified pinellia Tuber. The prescription is specially used for treating deficiency of defensive exterior and cold-dampness epidemic toxin invading lung and defensive qi, accumulating in upper-jiao of lung, transmitting to spleen and stomach of middle-jiao and attaching to lung and defensive collaterals in the process of COVID-19 asymptomatic disease according to the compatibility dosage of disease symptoms, and the epidemic toxin stays even though no symptom exists. The astragalus and the codonopsis pilosula are monarch drugs, the astragalus tonifies the spleen and the lung to remove cold-dampness evil, the exterior is protected from being invaded by cold-dampness exogenous evil, the codonopsis pilosula invigorates the spleen and benefits the lung to correct the qi deficiency of the spleen and the lung, and the qi and the fluid are promoted to prevent the evil from loving the body fluid, so that the astragalus and the codonopsis pilosula are used for strengthening the body resistance and resisting the evil together; pinellia ternate, pericarpium trichosanthis, bighead atractylodes rhizome, rhizoma atractylodis, poria cocos and dried orange peel are ministerial, pinellia ternate dispels cold and dampness, eliminates phlegm in lung, warms spleen and stomach, avoids middle-jiao yang damage, pericarpium trichosanthis is capable of reducing phlegm and clearing away heat, does not help cold pathogen to hurt yang, and also eliminates phlegm which is difficult to be brought out and benefits lung and viscera, rhizoma atractylodis macrocephalae and poria cocos tonify spleen and excrete dampness, warm and dispel cold to eliminate cold and dampness and epidemic toxin, rhizoma atractylodis dispels cold and dampness, invigorates spleen and avoids dirt, dispels wind and consolidates exterior, dried orange peel is capable of eliminating dampness and phlegm in lung, and resolving stagnation of dampness and turbidity of spleen and stomach; fructus amomi, radix sileris, almond, rhizoma wenyujin concinnatae and fried radix stemonae are used as adjuvant medicines, the fructus amomi warms the middle and dissipates dampness to eliminate cold and dampness, the radix sileris disperses the lung defense and defends the pathogenic wind to secure the defensive exterior, the almond ventilates the lung and eliminates phlegm to smooth the air passage, the rhizoma wenyujin concinnate the spleen and dispel blood stasis to clear away the collaterals and pathogenic toxin, after the radix stemonae is fried, the warm nature of the radix stemonae is enhanced, the lung protecting force is protected, and the effects of eliminating phlegm, dredging the breath and securing and protecting the lung are facilitated; the medicines dispel evil, tonify qi and strengthen superficies; in the recipe, Huoxiang serves as a guiding drug, which is fragrant, resolving dampness, avoiding turbidity and guiding various drugs, and is ascribed to lung and spleen. The whole formula is viewed comprehensively, the combination of the medicines can improve the immunity of a patient, strengthen vital qi, improve the lung function and expel lung toxin, and is a delicate part of the traditional Chinese medicine formula.
(2) The curative effect and the prescription analysis of the traditional Chinese medicine prescription
On the basis of the prescription, the research team continuously summarizes and searches in hospitals in epidemic areas and related epidemic-resistant work, accumulates the experience of treating the patients with the mild disease of the novel coronavirus pneumonia (COVID-19), and continuously fills and finishes the traditional Chinese medicine prescription aiming at the traditional Chinese medicine pathogenesis characteristics of the COVID-19 and the adverse situations that the curative effect of modern medicine treatment on the COVID-19 is poor and no specific medicine exists. Aiming at the situations of obvious CT change, nucleic acid positive and the like of a patient with mild COVID-19 symptoms and no symptoms, the syndrome is distinguished as epidemic toxin attacking the exterior. And the six meridians syndrome differentiation, the three jiao syndrome differentiation and the defense, qi, nutrient and blood syndrome differentiation together summarize the pathogenesis transmission rule of the asymptomatic phase of the typhoid, namely weak pathogen and deficiency of body resistance, lung and spleen deficiency, deficiency of both qi and yin and disharmony of three jiao.
And (3) separating: the whole formula focuses on the cold-dampness epidemic toxin attaching to the defense surface, and also considers the constitution of three factors, distinguishes the body and treats, strengthens the body resistance and eliminates the pathogenic factors. The traditional Chinese medicine composition is used for treating diseases such as dampness evil encumbering, qi disorder, dampness evil coagulation into mass and the like, and also for diagnosing and treating diseases such as cold dampness epidemic pathogenic factors such as qi deficiency and weakness, spleen and stomach encumbrance, phlegm obstruction and qi stagnation and the like, retention of lung defense, spleen and stomach, triple energizer and the like. Not only focuses on tonifying healthy qi of the body and improving the repair capability and tolerance capability of damaged organs, but also focuses on tonifying qi, strengthening exterior and arresting sweating, and improves the function of defending exterior and resisting pathogens against the loss of consolidation of skin and skin striae.
In the recipe, Huang Qi is sweet in flavor and warm in nature, enters spleen and lung meridians, tonifies qi of spleen and lung, and strengthens superficies to check sweating. In addition, radix astragali can enhance the effects of resisting free radical injury and lipid peroxidation, and can improve the resistance of organism to virus. In the formula, the codonopsis pilosula is sweet in taste and neutral in nature, enters spleen and lung channels, has the effects of tonifying middle-jiao and Qi, strengthening spleen and tonifying lung, nourishing blood and promoting fluid production, is used for treating spleen and lung qi deficiency, poor appetite and lassitude, cough and asthma, qi and blood deficiency, palpitation and shortness of breath, body fluid deficiency and internal heat and the like, and can be used for supplementing qi deficiency and correcting spleen and lung qi deficiency by being matched with monarch drugs; the two medicines are monarch medicines, and have the effects of tonifying yang and qi to resist the invasion of cold-dampness epidemic pathogen, reinforcing qi and consolidating superficial resistance to strengthen the defense system, tonifying qi and promoting the production of body fluid to prevent qi dryness and heat, and strengthening body resistance and resisting pathogen.
In the recipe, pinellia is pungent and warm, and enters spleen, stomach and lung meridians; has the functions of eliminating dampness and phlegm, calming adverse-rising energy and stopping vomiting, relieving distension and fullness and resolving masses, and is mainly used for treating damp-phlegm, cold-phlegm syndrome, vomiting, epigastric fullness, chest congestion and the like. The snakegourd peel is sweet, slightly bitter and cold in nature and enters lung and stomach meridians; clear lung heat and resolve phlegm, promote qi circulation, relieve chest stuffiness and dissipate nodulation. It can be used for treating cough due to lung heat, chest and hypochondrium pain, and sore throat. The medicine is combined with pinellia tuber to moisten dryness, and is a smart combination for adjusting the damp-cold constitution and clearing away the lung toxin and stagnated heat. In the formula, the bighead atractylodes rhizome is bitter and sweet in taste and warm in nature, enters spleen and stomach channels, strengthens spleen, tonifies qi, eliminates dampness and assists the astragalus root to strengthen the effects of tonifying qi and strengthening exterior. Atractylodis rhizoma has effects of invigorating spleen and stomach, strengthening body constitution and improving disease resistance. In the formula, the rhizoma atractylodis is pungent and bitter in taste and warm in nature, enters spleen, stomach and liver channels, and has the effects of eliminating dampness, strengthening spleen, dispelling wind and dispelling cold. In the formula, the poria cocos is sweet and light in taste and neutral in nature, enters heart, spleen and kidney channels, has the effects of promoting diuresis and excreting dampness, strengthening spleen and stomach, calming heart and soothing nerves, and pharmacology proves that the pachyman can enhance the immunologic function, strengthen the phagocytic function of abdominal cavity macrophages, resist pathogens and the like. The dried orange peel is pungent and bitter in taste and warm in nature, enters spleen and lung channels, and has the effects of regulating qi, strengthening spleen, eliminating dampness and reducing phlegm. The pinellia ternate, the pericarpium trichosanthis, the bighead atractylodes rhizome, the rhizoma atractylodis, the poria cocos and the pericarpium citri reticulatae are used as ministerial drugs to assist the monarch drugs in tonifying qi and strengthening body resistance, strengthening exterior and excreting dampness, dispelling cold and expelling wind and avoid the spleen, lung and defensive exterior from being invaded by cold-dampness epidemic pathogenic factors.
The fructus amomi in the prescription has pungent taste and warm property, enters spleen and stomach meridians, and has the effects of promoting qi circulation, relieving epigastric distention, strengthening spleen and eliminating dampness. The pharmacology proves that the fructus amomi compound preparation can resist myocardial anoxia, adjust the immunologic function and the like. In the formula, the divaricate saposhnikovia root is pungent, sweet and slightly warm and enters bladder, lung, liver and spleen channels, so that the divaricate saposhnikovia root is assisted to prevent wind from going out of the surface to disperse wind evil, the astragalus and the largehead atractylodes rhizome are combined to tonify qi and eliminate evil, the astragalus can be the divaricate saposhnikovia root, the exterior is fixed without retaining evil, the divaricate saposhnikovia root can be the astragalus, the evil is eliminated without damaging the body resistance, and the effects of strengthening the middle-jiao and dredging the middle-jiao and dispersing the tonifying are achieved. In the formula, the almond is bitter in taste, warm in nature, toxic and capable of entering lung and large intestine channels, and has the effects of eliminating phlegm, relieving cough, relieving asthma and the like. In the recipe, the turmeric root tuber, rhizoma Curcumae Longae, pungent, bitter and warm in flavor, enters liver and spleen meridians, breaks blood and promotes qi circulation, and clears meridians to stop pain, and is used for chest and hypochondrium pain, rheumatalgia and the like. For cold-dampness epidemic febrile disease, toxic and insect pathogen, qi obstruction and lung impairment, radix Stemonae preparata is added during formula selection, and is used for treating cough, asthenia, etc. due to its sweet, bitter and slightly warm nature, which specially enters lung meridian. The five medicines of the amomum fruit, the divaricate saposhnikovia root, the almond, the rhizoma wenyujin concubie and the fried sessile stemona root are used together as an adjuvant to jointly form a preparation for strengthening the spleen and supplementing qi, regulating the middle warmer and harmonizing the stomach, supplementing qi and consolidating the exterior, and has the effects of regulating the stagnation of qi, strengthening the body resistance, evacuating internal and external cold-dampness and stasis and the like. Especially has good curative effect on the patients with the upper respiratory tract infection which is easily infected by exogenous pathogenic factors due to the insecurity of exterior and also on the patients with the viscera of weak qi and the deficiency of healthy qi which are easily attacked by wind and pathogenic factors and the repeated pathogenic conditions.
In the recipe, wrinkled gianthyssop herb is slightly warm in nature and pungent in taste, specially enters spleen and lung meridians, is fragrant in qi and good at promoting the circulation of stomach qi, regulates middle energizer to treat vomiting and cholera, quickly dispels foul and stuffy in feeling, can harmonize five internal organs, helps stomach and eat if the spleen and stomach are not harmonized, has the functions of activating spleen and stimulating appetite, is pungent to relieve nine orifices, does not invade exogenous pathogenic factors internally if used for miasma epidemic disease, has the function of regulating vital qi, is various qi-regulating medicines, is light and warm in body and can nourish lung and stomach. It is used as adjuvant and has the effect of guiding drugs, not only eliminating dampness and dissolving turbidity to resist cold-dampness and epidemic toxin, but also strengthening body resistance and consolidating exterior to resist external cooperation, and moving qi of middle-upper energizer to dissipate dampness, and it specially walks the property of spleen and lung channels to direct the drugs to the disease sites such as defense-surface, lung and spleen.
The combination of the medicines can achieve the effects of invigorating qi, eliminating phlegm, dispelling cold, eliminating dampness, strengthening exterior, strengthening defense, and transporting and transforming middle-jiao. NeedleFor various constitutions, the weak defensive qi striae, weak middle-jiao deficiency and weak healthy qi, lung deficiency with wind pathogen, spleen deficiency with dampness, yang deficiency with cold-dampness retention, and deficient healthy qi failing to secure exterior, yin deficiency and fluid discharge, spontaneous sweating and dripping, and complexion
The symptoms of cold-dampness pathogen infection with white tongue, pale tongue with thin and white fur and floating and deficient pulse are all the categories of syndrome treatment of the traditional Chinese medicine.
Advantageous effects
In order to accurately illustrate the clinical significant effect of the traditional Chinese medicine prescription, 564 large-sample clinical case observation studies are carried out on the clinical curative effect results of hospitals, the clinical curative effect results show that about 112 asymptomatic patients account for 19.9 percent of all patients, the age distribution is 22-58 years, 72 male patients and 40 female patients are all mild patients without obvious symptoms, and all patients are positive in nucleic acid detection. Among them, 20 cases of mild vitreotic inflammatory exudation of lung accounted for 17.9% of asymptomatic patients, 15 cases of mild nodular inflammatory exudation accounted for 13.4% of asymptomatic patients, 50 cases of mild regional inflammatory exudation, 44.6% of asymptomatic patients, 20 cases of moderate multifocal inflammatory exudation, 17.9% of asymptomatic patients, 7 cases of moderate large-area inflammatory exudation, 6.3% of asymptomatic patients, 80 cases of bilateral lobe affected patients, 71.4% of asymptomatic patients, 32 cases of unilateral lobe affected patients, 28.6% of asymptomatic patients, 23 cases of inflammatory exudation accompanied by bronchoscopy, 20.5% of asymptomatic patients, 1 case of inflammatory exudation accompanied by small amount of pleural effusion, and 0.9% of asymptomatic patients. After the Chinese medicinal preparation is used for treating 7-20 days, the chest CT of the treated asymptomatic novel coronavirus pneumonia (COVID-19) mild patient indicates that inflammatory exudation is obvious or completely absorbed, the positive negative conversion time is shortened by regular throat swab nucleic acid examination, the hospitalization time is further shortened, one patient who is admitted again due to negative conversion to positive is not shown, the number of neutrophilic granulocytes in blood of all mild patients is reduced, the number of lymphocytes is gradually increased, the lymph ratio is increased along with the change of symptoms, and the clinical effects of ' zero severe, zero death and ' zero sun recovery ' of the patient treated by the Chinese medicinal preparation are finally realized. The action mechanism of the prescription of the invention is suggested to play an antiviral role in promoting the sputum excretion of the respiratory system, relieving the inflammatory reaction of the lower respiratory tract and enhancing the resistance of the organism to viruses. In addition, the image data shows that the inflammatory exudation is reduced, which indicates that the prescription has the functions of repairing lung tissue injury, removing free radicals and inhibiting proinflammatory complement reaction on the basis of anti-inflammation.
The beneficial technical effects specifically summarized according to the clinic are as follows:
(1) the traditional Chinese medicine formula disclosed by the invention overcomes the difficulty of treating patients with light symptom of asymptomatic novel coronavirus pneumonia (COVID-19) through scientific formula and exploratory application. The traditional Chinese medicine formula is ingenious and refined in compatibility, and clinical application proves that the traditional Chinese medicine formula can effectively prevent patients with COVID-19 mild symptoms from becoming severe, protect the respiratory function of the lung to a certain extent, relieve various anoxia symptoms of the patients with COVID-19 mild symptoms after long-term use, and promote the recovery of the patients.
(2) The traditional Chinese medicine formula can obviously improve chest CT (computed tomography) prompting inflammatory exudation of a novel coronavirus pneumonia (COVID-19) mild patient, shorten the negative turning time of throat swab nucleic acid examination, block the decrease of the number of blood neutrophils of all mild patients, enable the number of lymphocytes to gradually increase, and enable the lymph ratio to rise along with the symptom.
Detailed Description
The traditional Chinese medicine preparation disclosed by the invention is already applied to the clinical practice treatment of COVID-19, and a large case sample is used for treating the asymptomatic positive novel coronavirus pneumonia in a hospital. The traditional Chinese medicine is prepared by closely following the syndrome differentiation and treatment of traditional Chinese medicines. For this reason, clinical efficacy data of certain representative COVID-19 asymptomatic patients are selected to illustrate the workable process of the present invention, but the embodiments of the present invention are not limited thereto.
EXAMPLE 1 preparation of the asymptomatic positive Xinguan pneumonia basic prescription of the present invention
A. The composition ratio is as follows: 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of pericarpium trichosanthis, 10g of roasted radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter almond, 5g of rhizoma wenyujin concinnae and 10g of rhizoma pinelliae preparata;
B. the preparation method comprises the following steps: soaking the traditional Chinese medicine raw materials in the weight part ratio in the step A in water, placing the soaked traditional Chinese medicine raw materials in an extraction tank for 2 times, extracting for 1-2 hours, filtering to obtain a liquid, mixing all filtered liquid phases, and concentrating to obtain a raw material liquid containing 1g crude medicine per ml; then preparing into decoction, capsule, pill, granule, tablet or oral liquid according to conventional method.
In addition, the composition proportion of the Chinese medicinal formula A can be implemented in the following way, and the preparation method adopts the same method as the composition proportion of the Chinese medicinal formula B:
A1. the composition ratio is as follows: 5g of codonopsis pilosula, 8g of fried bighead atractylodes rhizome, 8g of rhizoma atractylodis, 3g of poria cocos, 3g of dried orange peel, 8g of wrinkled gianthyssop herb, 5g of fructus amomi, 6g of pericarpium trichosanthis, 12g of fried radix stemonae, 18g of raw astragalus membranaceus, 8g of divaricate saposhnikovia root, 5g of bitter apricot kernel, 3g of rhizoma wenyujin concinnae and 6g of rhizoma pinelliae preparata;
A2. the composition ratio is as follows: 10g of codonopsis pilosula, 3g of fried bighead atractylodes rhizome, 3g of rhizoma atractylodis, 8g of poria cocos, 8g of dried orange peel, 3g of wrinkled gianthyssop herb, 2g of fructus amomi, 12g of pericarpium trichosanthis, 6g of roasted radix stemonae, 10g of raw astragalus membranaceus, 3g of radix sileris, 2g of bitter apricot kernel, 8g of rhizoma wenyujin concinnatae and 12g of rhizoma pinelliae preparata;
A3. the composition ratio is as follows: 3g of codonopsis pilosula, 6g of fried bighead atractylodes rhizome, 6g of rhizoma atractylodis, 10g of poria cocos, 10g of dried orange peel, 5g of wrinkled gianthyssop, 3g of fructus amomi, 6g of pericarpium trichosanthis, 6g of roasted radix stemonae, 10g of raw astragalus membranaceus, 10g of divaricate saposhnikovia root, 6g of bitter almond, 5g of rhizoma wenyujin concinnatae and 15g of rhizoma pinelliae preparata;
A4. the composition ratio is as follows: 12g of codonopsis pilosula, 10g of fried bighead atractylodes rhizome, 10g of rhizoma atractylodis, 10g of poria cocos, 3g of dried orange peel, 10g of wrinkled gianthyssop herb, 6g of fructus amomi, 15g of pericarpium trichosanthis, 15g of roasted radix stemonae, 20g of raw astragalus membranaceus, 10g of divaricate saposhnikovia root, 6g of bitter apricot seed, 10g of rhizoma wenyujin concinnae and 15g of rhizoma pinelliae preparata.
EXAMPLE 2 preparation of the asymptomatic nucleic acid-positive and yang-deficiency cold-type physical disease syndrome traditional Chinese medicine formulation of the present invention
A. The composition ratio is as follows: 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of pericarpium trichosanthis, 10g of fried radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter apricot kernel, 5g of rhizoma wenyujin concinnatae, 10g of rhizoma pinelliae preparata, 3g of cinnamon and 5g of dried ginger.
B. The preparation method comprises the following steps: the procedure is as in "preparation A" in example 1.
EXAMPLE 3 preparation of the asymptomatic nucleic acid-positive febrile physical disease syndrome-treating Chinese medicinal preparation of the present invention
A. The composition ratio is as follows: 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of pericarpium trichosanthis, 10g of fried radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter apricot kernel, 5g of rhizoma wenyujin concinnae, 10g of rhizoma pinelliae preparata, 5g of coptis chinensis and 10g of lalang grass rhizome.
B. The preparation method comprises the following steps: the procedure is as in "preparation A" in example 1.
EXAMPLE 4 preparation of the asymptomatic nucleic acid-positive and Damp-type physical Condition Chinese medicinal preparation of the present invention
A. The composition ratio is as follows: 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of pericarpium trichosanthis, 10g of fried radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter apricot kernel, 5g of rhizoma wenyujin concinnae, 10g of rhizoma pinelliae preparata, 10g of herba eupatorii and 10g of semen coicis.
B. The preparation method comprises the following steps: the procedure is as in "preparation A" in example 1.
EXAMPLE 5 preparation of the asymptomatic nucleic acid-positive and yin-deficiency-fire-deficient constitution disease Chinese medicinal preparation of the present invention
A. The traditional Chinese medicine composition comprises 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of trichosanthes peel, 10g of fried radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter apricot seed, 5g of rhizoma curcumae longae, 10g of rhizoma pinelliae preparata, 10g of radix ophiopogonis and 10g of rhizoma polygonati.
B. The preparation method comprises the following steps: the procedure is as in "preparation A" in example 1.
EXAMPLE 6 preparation of the asymptomatic nucleic acid-positive and qi-deficiency and blood-stasis-type disease-curing traditional Chinese medicine formulation of the present invention
A. The composition ratio is as follows: 6g of codonopsis pilosula, 5g of fried bighead atractylodes rhizome, 5g of rhizoma atractylodis, 5g of poria cocos, 5g of dried orange peel, 5g of wrinkled gianthyssop herb, 3g of fructus amomi, 10g of pericarpium trichosanthis, 10g of fried radix stemonae, 15g of raw astragalus membranaceus, 5g of divaricate saposhnikovia root, 3g of bitter apricot kernel, 5g of rhizoma wenyujin concisum, 10g of rhizoma pinelliae preparata, 10g of hyacinth bean.
B. The preparation method comprises the following steps: the procedure is as in "preparation A" in example 1.
EXAMPLE 7 curative effects of COVID-19 on asymptomatic clinical cases with yang deficiency and cold constitution
Chua certain sex: male, age: age 21. The 'novel coronavirus pneumonia' is confirmed to be admitted in 2 days, the nucleic acid of the patient is detected to be positive in 2 months and 15 days, and the lung is shown to be exuded by CT (computed tomography), so that no special discomfort exists. A superficial, slippery and weak pulse with a thin, white and greasy coating. The traditional Chinese medicine is dialectical of yang deficiency and damp stagnation. The Chinese medicinal composition prepared in "example 2" of the present invention was administered for two weeks. After two weeks the blood picture was normal, CT chest inflammatory exudative absorption, nucleic acid negative.
EXAMPLE 8 curative effects of clinical cases of asymptomatic and febrile physical disorders with COVID-19
Somebody of yellow, sex: male, age: age 19. After half a month of repeated fever, the hospital is admitted for 6 days to confirm the 'novel coronavirus pneumonia', the nucleic acid is checked to be positive after 10 days in 2 months, the CT lung texture is thickened, inflammatory exudation is caused, and the oseltamivir and the Lianhua antipyretic capsule are orally taken, so that no special discomfort exists. A superficial, slippery, surging, powerful pulse with yellow, thick and greasy coating. Traditional Chinese medicine distinguishes the syndrome of damp-heat in the interior. The Chinese medicinal composition prepared in "example 3" of the present invention was administered for two weeks. CT chest inflammatory exudative absorption after one week, nucleic acid negative.
EXAMPLE 9 curative effects of COVID-19 on asymptomatic and damp constitutional clinical cases
Certain Pan, sex: male, age: age 40. The new coronary pneumonia is confirmed to be diagnosed for 1 day and is planned to be further treated. Because father of the patient is infected with the new coronary pneumonia, the patient is isolated in the hotel in 13 months, CT abnormality is checked in 13 days, the patient is checked to be positive in the new coronary nucleic acid in 14 days, and hospitalization is carried out. Ping Su is fat and weak and moving. Admission chest CT suggested a little inflammatory exudation. Deep and slippery pulse, thick and greasy coating. TCM distinguishes the syndrome of dampness stagnating. The Chinese medicinal composition prepared in "example 4" of the present invention was administered for two weeks. CT chest inflammatory exudation absorption after 10 days, nucleic acid negative.
EXAMPLE 10 curative effects of COVID-19 on asymptomatic clinical cases accompanied by yin deficiency and deficient fire
Somebody, sex: male, age: age 38. New coronary pneumonia was confirmed for 8 days. The test of positive nucleic acid and abnormal CT test in 2, 7 and 7 days, and the moxifloxacin is orally taken, so that no special discomfort exists. Plain body is healthy, body is thin, occasionally night sweats. Admission chest CT suggested mild inflammatory exudation. The six superficial, thready and rapid pulse, dry red tongue with little coating and greasy coating on the root of the tongue. Traditional Chinese medicine dialectical deficiency fire disturbing internally. The Chinese medicinal composition prepared in "example 5" of the present invention was administered for two weeks. CT chest inflammatory exudation absorption after 12 days, nucleic acid negative.
Example 11 curative effects of clinical cases of asymptomatic, qi deficiency and blood stasis with COVID-19
Certain populus, sex: female, age: age 37. The novel coronary pneumonia was confirmed for 4 days. The detection of nucleic acid is positive before 4 days, and the chest CT is examined later to show that the lung has exudation and no discomfort. Laziness in speaking, hypokinesia, irregular menstruation, and few blood clots. Deep, thready and unsmooth pulse, pale tongue with petechia, thin and white coating. Traditional Chinese medicine is used for dialectical qi deficiency and blood stasis. The Chinese medicinal composition prepared in "example 5" of the present invention was administered for two weeks. CT chest inflammatory exudation was completely absorbed after 15 days, and was nucleic acid negative. After 15 days, the sleep quality is good, the weakness and cough disappear, the shortness of breath and no desire to speak improve, the patient can sit and walk for a long time, the inflammatory exudation of the chest of the CT is completely absorbed, and the nucleic acid is negative.
EXAMPLE 12 curative effects of clinical cases of asymptomatic positive pneumonia with COVID-19
Somebody of the skin, gender: male, age: age 35. The novel coronary pneumonia was confirmed for 11 days. The novel coronavirus pneumonia is confirmed by a patient at home, 02.09 communities are isolated, 02.15 positive detection of the new coronavirus nucleic acid is carried out, 02.17 the patient is admitted to a hospital, CT (computed tomography) of admission prompts of pneumonia of left lung, tongue and double lower lung, infection resistance, virus resistance and traditional Chinese medicine treatment are carried out, and 02.23 positive detection of the new coronavirus nucleic acid is carried out. Since the diagnosis is confirmed, the patient has no symptoms of fever, hypodynamia, palpitation, chest distress, shortness of breath, diarrhea and the like, and the general condition is good. A superficial, large and powerful pulse, a pale tongue with a thin and white coating. The traditional Chinese medicine is used for dialectical symptomless treatment and external infection epidemic toxin. The Chinese medicinal composition prepared in "example 1A 4" of the present invention was administered for 15 days in succession. CT chest inflammatory exudation was completely absorbed after 10 days, and was nucleic acid negative.
Claims (11)
1. A traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia is characterized by being prepared from the following raw material medicines in parts by weight: 3-12 parts of codonopsis pilosula, 3-10 parts of fried bighead atractylodes rhizome, 3-10 parts of rhizoma atractylodis, 3-10 parts of poria cocos, 3-10 parts of dried orange peel, 3-10 parts of wrinkled gianthyssop herb, 2-6 parts of fructus amomi, 6-15 parts of pericarpium trichosanthis, 6-15 parts of roasted radix stemonae, 10-20 parts of raw astragalus membranaceus, 3-10 parts of divaricate saposhnikovia root, 2-6 parts of bitter apricot seed, 3-10 parts of rhizoma curcumae longae and 6-15 parts of rhizoma pinelliae preparata.
2. The traditional Chinese medicine composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 1, which comprises the following components in parts by weight: 5-10 parts of codonopsis pilosula, 3-8 parts of fried bighead atractylodes rhizome, 3-8 parts of rhizoma atractylodis, 3-8 parts of poria cocos, 3-8 parts of dried orange peel, 3-8 parts of wrinkled gianthyssop herb, 2-5 parts of fructus amomi, 6-12 parts of pericarpium trichosanthis, 6-12 parts of roasted radix stemonae, 10-18 parts of raw astragalus membranaceus, 3-8 parts of divaricate saposhnikovia root, 2-5 parts of bitter apricot seed, 3-8 parts of rhizoma curcumae longae and 6-12 parts of rhizoma pinelliae preparata.
3. The traditional Chinese medicine composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 2, which comprises the following components in parts by weight: 6 parts of codonopsis pilosula, 5 parts of fried bighead atractylodes rhizome, 5 parts of rhizoma atractylodis, 5 parts of poria cocos, 5 parts of dried orange peel, 5 parts of wrinkled gianthyssop herb, 3 parts of fructus amomi, 10 parts of pericarpium trichosanthis, 10 parts of roasted radix stemonae, 15 parts of raw astragalus membranaceus, 5 parts of divaricate saposhnikovia root, 3 parts of bitter almond, 5 parts of rhizoma wenyujin concinnae and 10 parts of rhizoma pinelliae preparata.
4. The traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia according to claim 3, which is characterized by combining yang deficiency and cold constitutional disease, and further comprises the following raw material medicines in parts by weight: 3 parts of cinnamon and 5 parts of dried ginger.
5. The traditional Chinese medicine composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 3, which is characterized by accompanying with a febrile physical disease, and further comprises the following raw material medicines in parts by weight: 5 parts of coptis chinensis and 10 parts of cogongrass rhizome.
6. The traditional Chinese medicine composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 3, which is compatible with the damp constitutional disease, and further comprises the following raw material medicines in parts by weight: 10 parts of eupatorium and 10 parts of coix seeds.
7. The traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia according to claim 3, which is accompanied by yin deficiency and deficient fire constitutional diseases, and further comprises the following raw material medicines in parts by weight: 10 parts of radix ophiopogonis and 10 parts of rhizoma polygonati.
8. The traditional Chinese medicine composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 3, which is characterized by symptoms of both qi deficiency and blood stasis, and further comprises the following raw material medicines in parts by weight: 10 parts of hyacinth bean, 10 parts of gordon euryale seed and 6 parts of salvia miltiorrhiza.
9. The Chinese medicinal composition for treating the asymptomatic nucleic acid-positive novel coronavirus pneumonia according to any one of claims 1 to 8, wherein the dosage form of the Chinese medicinal composition is decoction, capsule, pill, granule, tablet or oral liquid.
10. The Chinese medicinal composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 9, wherein the novel coronavirus is COVID-19.
11. The use of the Chinese medicinal composition for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia according to claim 10 as an active ingredient in the preparation of a medicament for treating asymptomatic nucleic acid-positive novel coronavirus pneumonia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010393398.5A CN111643634B (en) | 2020-05-11 | 2020-05-11 | Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010393398.5A CN111643634B (en) | 2020-05-11 | 2020-05-11 | Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111643634A CN111643634A (en) | 2020-09-11 |
| CN111643634B true CN111643634B (en) | 2021-09-07 |
Family
ID=72352273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010393398.5A Active CN111643634B (en) | 2020-05-11 | 2020-05-11 | Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111643634B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616742B (en) * | 2020-05-08 | 2022-06-17 | 江苏省中医院 | Traditional Chinese medicine composition for treating lung and spleen deficiency of pulmonary diseases and preparation method and application thereof |
| CN113398219A (en) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | Application of exocarpium citri rubrum extract for preparing medicine for inhibiting human coronavirus infection |
| CN118078763A (en) * | 2024-04-24 | 2024-05-28 | 江西中医药大学附属医院 | Granule for strengthening body resistance, eliminating dampness and resisting toxicity and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130019A (en) * | 2007-08-21 | 2008-02-27 | 王军 | Powder of ginseng for regulating the stomach |
| CN103405707A (en) * | 2013-08-28 | 2013-11-27 | 陈宏志 | Chinese medicine preparation for regulating ti-flowing for strengthening spleen and eliminating dampness and phlegm |
| CN105435084A (en) * | 2016-01-12 | 2016-03-30 | 叶庆 | Traditional Chinese medicine having effects of invigorating spleen and removing damp and preparation method thereof |
-
2020
- 2020-05-11 CN CN202010393398.5A patent/CN111643634B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130019A (en) * | 2007-08-21 | 2008-02-27 | 王军 | Powder of ginseng for regulating the stomach |
| CN103405707A (en) * | 2013-08-28 | 2013-11-27 | 陈宏志 | Chinese medicine preparation for regulating ti-flowing for strengthening spleen and eliminating dampness and phlegm |
| CN105435084A (en) * | 2016-01-12 | 2016-03-30 | 叶庆 | Traditional Chinese medicine having effects of invigorating spleen and removing damp and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| Core Outcome Set for Clinical Trials on Coronavirus Disease 2019;Xinyao Jin;《Engineering》;20200318;1147-1300 * |
| 同济医院中医科专家制定《新型冠状病毒感染的肺炎中医诊疗方案及预防方案》;人民网;《http://hb.people.com.cn/n2/2020/0208/c194063-33776830.html》;20200208;1 * |
| 新型冠状病毒肺炎中医临床特征;王玉光;《中医杂志》;20200229;第61卷(第4期);281-285 * |
| 民族医药对新型冠状病毒肺炎的认识及防治措施;张吉仲;《中草药》;20200331;第51卷(第6期);1463-1475 * |
| 道医堂：新冠肺炎第七版方案推荐了十个中药处方;深圳道医堂;《https://m.sohu.com/a/380560324_100118137》;20200331;1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111643634A (en) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111671880B (en) | Traditional Chinese medicine preparation for treating fever caused by coronavirus pneumonia | |
| CN111643634B (en) | Traditional Chinese medicine composition for treating asymptomatic nucleic acid positive novel coronavirus pneumonia | |
| CN111671867B (en) | Novel traditional Chinese medicine composition for treating mild coronary virus pneumonia cough | |
| CN102058767B (en) | Chinese medicine for treating senile chronic bronchitis and method for preparing pills thereof | |
| CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN111773308A (en) | Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method | |
| CN103520395A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN111467459B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia at recovery stage, application and preparation method thereof | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN111569010A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating neocoronary pneumonia | |
| CN111671868B (en) | Novel traditional Chinese medicine composition for treating mild symptoms, namely coronavirus pneumonia and insomnia | |
| CN102793868B (en) | Preparation method of traditional Chinese medicine lotion for treating rapid respiration type closed fracture | |
| CN101596270A (en) | A kind of medicine that is used for the treatment of chronic pharyngitis and preparation method thereof | |
| CN116036202B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, and preparation method and application thereof | |
| CN111184805A (en) | Traditional Chinese medicine composition and application thereof | |
| CN115998824B (en) | Traditional Chinese medicine composition for clearing damp and detoxicating, and preparation method and application thereof | |
| CN103623103B (en) | Traditional Chinese medicine preparation for treating coughing and phlegmy throat | |
| CN107115454A (en) | It is a kind of effectively to treat Chinese medicine composition of pneumonia and preparation method thereof | |
| CN106668669A (en) | Traditional Chinese medicine formula for treating cough variant asthma | |
| CN106334155A (en) | Traditional Chinese medicine composition for treating arterial thyromegaly and preparation method thereof | |
| CN104491637A (en) | Compound combination medicine for treating postinfectious cough as well as preparation method and application of compound combination medicine | |
| CN112023005A (en) | Traditional Chinese medicine preparation for treating viral hepatitis and preparation method thereof | |
| CN115804820A (en) | Pharmaceutical composition for treating wind-heat dry cough and preparation and application thereof | |
| CN104474184A (en) | Medicine for treating postinfectious cough | |
| CN116585382A (en) | Rehabilitation traditional Chinese medicine preparation beneficial to virus infection pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240428 Address after: 710075 Room 901, Building E1-9, Yungu Phase I, West Fengxi New City, Xixian New Area, Xi'an City, Shaanxi Province Patentee after: Shaanxi Baichuan Grass Biotechnology Co.,Ltd. Country or region after: China Address before: 100010 No. 23, back street, Dongcheng District Art Museum, Beijing Patentee before: BEIJING CHINESE MEDICINE HOSPITAL AFFILIATED CAPITAL MEDICAL University Country or region before: China Patentee before: SHAANXI UNIVERSITY OF CHINESE MEDICINE AFFILIATED Hospital |
|
| TR01 | Transfer of patent right |